Clinical trial · no report yet · Phase 1
ARC-20
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- NCT05536141 ↗
- Recruiting
- Arcus Biosciences, Inc.
- 49 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 25 | |
| YouTube | 12 | |
| Podcasts | 11 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Clear Cell Renal Cell Carcinoma; Solid Tumors
- Interventions
- casdatifan; Cabozantinib; Zimberelimab; Ipilimumab
- Arms
- Dose Escalation Cohort 1 · Experimental
- Dose Escalation Cohort 2 · Experimental
- Dose Escalation Cohort 3 · Experimental
- Dose Escalation Cohort 4 · Experimental
- Dose Escalation Cohort 5 · Experimental
- Dose Expansion Cohort 1 · Experimental
- Dose Expansion Cohort 2 · Experimental
- Dose Expansion Cohort 3 · Experimental
- Dose Expansion Cohort 4 · Experimental
- Dose Expansion Cohort 5 · Experimental
- Dose Expansion Cohort 6 · Experimental
- Dose Expansion Cohort 7 · Experimental
- Dose Expansion Cohort 8 · Experimental
- Dose Expansion Cohort 9 · Experimental
- Dose Expansion Cohort 10 · Experimental
- Enrollment
- 362 (estimated)
- Primary outcomes
- Number of participants with dose limiting toxicities (DLTs)
- Number of participants with adverse events (AEs)
- Sponsor
- Arcus Biosciences, Inc.
- Start
- Oct 26, 2022
- Primary completion
- Mar 2029 (estimated)
- Results posted
- No
- Registry record
- NCT05536141 · updated Oct 5, 2026